Introduction to a Patient Reference Guide to Dupixent and Cancer Risk

  • Dupixent (dupilumab): Is an injectable biologic medication that is used to treat particular types of inflammatory diseases. The medicine is currently the subject of a growing number of lawsuits alleging it causes or accelerates the development of cutaneous T-cell lymphoma (CTCL), a rare form of cancer. As of November 2025, the litigation is in early stages, with no settlements or jury verdicts yet.
  • Recent studies on Dupixent and Cancer:  Have shown that Dupixent use may increase the risk of certain types of cancers known as Cutaneous T-cell Lymphomas (CTCL), including its subtypes Mycosis fungoides and Sezary syndrome, by as much as 300% or more in people who used the medication.
  • Potential Compensation: People who used Dupixent and were later diagnosed with CTCL may be eligible to file a Dupixent Cancer Lawsuit and potential entitled to substantial compensation. If you suffered Dupixent and Cancer call Dupixent Cancer Lawyer Timothy L. Miles today for a free case evaluation. (855)-846-6529 or [email protected].

THE DUPLXENT COMMON SIDE EFFECCTS PROFILE

Dupixent side effects provide used in Dupixent and Cancer Risk

Summary of Key Information on Dupixent and Cancer Risk

  • Increased Dupixent and Cancer Risk Factor: One 2024 study published in the Journal of the American Academy of Dermatology found that atopic dermatitis patients treated with Dupixent were more than four times (4.1-fold) more likely to develop CTCL compared to patients who did not use the drug. Another study suggested that Dupixent users reported CTCL 30 times more often than users of all other medications in FDA safety data.
  • Second Dupixent and Cancer Study: A second study in 2024, published in Dermatologic Therapy, similarly reported an increased risk of CTCL among Dupixent users. The study alson noted that the risk was highest within the first year of treatment, and people over 60 were more susceptible.

Medicine concept: text Side Effect on Black chalkboard on grunge wall background, 3D rendering used in FDA approved concept. Rubber stamp with FDA and medicine. 3d illustration

Recommendations for Patients

  • Do not stop taking Dupixent without consulting your doctor:. The benefits of managing conditions like severe eczema and asthma may outweigh the potential risks, but a medical professional should make that assessment.
  • Be Cognizant of Warning Signs: Patients currently using Dupixent should watch for warning signs and discuss any concerns with their healthcare provider: 
    • Skin rashes that do not heal or are atypical.
    • Unexplained lumps or thickened skin patches.
    • Swollen lymph nodes.
    • Hair loss (in the context of new skin changes). 

The Dupixent Mechanism of Action

  • Blocks Two Key Proteins: These interleukins are central drivers of type 2 inflammation, which is the underlying cause of conditions like severe asthma, atopic dermatitis (eczema), and chronic rhinosinusitis with nasal polyps.

Key Aspects of the Mechanism of Action

  • The Impact: This targeted action helps to “calm” an overreactive immune system and mitigate the chronic inflammation responsible for the symptoms of associated diseases, without causing broad immunosuppression. By targeting the common pathway, Dupixent can treat multiple type 2 inflammatory conditions simultaneously.

Most Common Side Effect of Dupixent on the Eyes

Most Common Side Effect: The most common side effect of Dupixent on the eyes is conjunctivitis (pink eye). Other potential eye-related side effects include dry eyes, eyelid inflammation (blepharitis), and corneal inflammation (keratitis). These issues occur most frequently in patients being treated for atopic dermatitis (eczema) 

Common Ocular Side Effects

Most eye problems associated with Dupixent are mild to moderate and can be managed with treatment, often allowing the patient to continue using the medication.
Conjunctivitis: This is the most frequently reported side effect, affecting as many as 1 in 4 patients in some studies.
    • Symptoms: Redness, itching, a gritty feeling (like a foreign body is in the eye), watery or sticky discharge, and swollen eyelids.
  • Dry Eye: This can cause dryness, burning, and irritation. The drug blocks a protein (IL-13) that helps maintain mucus production and the stability of the tear film, leading to dryness and irritation.

Rare but Serious Complications

While less common, more severe issues have been reported and require urgent medical attention. 

When to Seek Medical Help

It is important to promptly report any new or worsening eye symptoms to your healthcare provider. They may refer you to an ophthalmologist (eye specialist) for an exam. 
Seek urgent ophthalmology evaluation if you experience: 
  • Significant eye pain that doesn’t go away.
  • Sudden changes in vision or vision loss.
  • Intense light sensitivity.
  • Visible damage or an opaque spot on the cornea.

Dupixent and cancer

Other Common Side Effects (Non-Ocular)

The most frequent side effects that are not related to the eyes include: 
  • Injection site reactions: This is the most common side effect, involving redness, swelling, pain, itching, or bruising at the site of the injection.

How to Manage Ocular Side Effects

  • Mild Dubixent Side Effects: These side effects of Dupixent are mainly mild, resolve on their own, and are bit critical enough to lead to stopping the medication. Neverthesee, in certain instances, additional treatment may become necessary to manage Dupixent side effects.
  • Management of Dupixent side effects to the Eyes: The management of vision Dupixent side effects depends on the severity of the condition. Mild cases may only need over-the-counter (OTC) and home remedies, such as:
    • artificial tears (eye drops to improve the eye’s moisture)
    • hyaluronic eye drops
    • cold compresses
    • warm compresses
    • antihistamines to manage inflammation
    • gentle eyelid scrubs for blepharitis

The Basis for a Dupixent Cancer Lawsuit

  • Primary Basis Dupixent and Cancer Lawsuits: The central claim in the lawsuits is “failure to warn“. Plaintiffs argue that the manufacturers knew or should have known about the potential link between Dupixent and CTCL based on emerging medical studies and adverse event reports, yet did not update the product’s warning label.
  • Key Points: Critical points supporting the litigation include:
    • FDA Investigation: In March 2025, the U.S. Food and Drug Administration (FDA) identified CTCL as a “potential signal of a serious risk” associated with Dupixent and opened a formal safety investigation. The FDA is currently evaluating whether to require a label change.
    • Masking Symptoms: CTCL often initially appears as skin patches that can be mistaken for eczema. Lawsuits allege that Dupixent’s mechanism of action may “unmask” a pre-existing, undiagnosed lymphoma or accelerate its progression, delaying proper cancer diagnosis and treatment.
    • First Wrongful Death Suit: A wrongful death lawsuit was filed in October 2025 by the family of a Tennessee woman who died from T-cell lymphoma shortly after starting Dupixent treatment, marking a significant development in the litigation.

Dupixent and Cancer Risk

Patient Reports of Cancer Linked to Dupixent

  • Patient and Healthcare Reports on FAERS: In addition to the clinical research and studies, the U.S. Federal and Drug Administration’s (FDA),  Adverse Event Reporting System (FAERS) included numerous patient reports and reports from healthcare providers linking Dupixent (dupilumab) to cancer, specifically to multiple types of T-cell lymphoma. FAERS is a vital database that regulators and researchers use to recognize potential drug risks requiring further investigation.
  • Reports Confirm Clinical Research: As you will note by visiting FAERS from the button below, the current dashboard shows close to 300 reports of T-cell lymphoma cases among Dupixent patients, which includes confirmed reports of cutaneous T-cell lymphoma (CTCL) and other related and serious conditions. These patient and healthcare reports to the FDA continue to fuel concerns that was addressed in clinical studies, strengthening the need for doctors to closely monitoring patients taking Dupixent.
  • The database shows the following type of cases have been reported by patients taking Dupixent or reported by healthcare providers:
    • Cutaneous T-Cell Lymphoma
    • Adult T-Cell Lymphoma/Leukemia
    • T-Cell Lymphoma (general)
    • CTCL, Stage IV
    • CTCL, Stage III
    • Angioimmunoblastic T-Cell Lymphoma
    • CTCL, Stage I
    • Recurrent T-Cell Lymphoma
    • Lymphoma (unspecified)
    • Anaplastic Large Cell Lymphoma (T- and null-cell types)
    • Unclassifiable T-Cell Lymphoma
  • Volume of Reports:  The vast volume of these reports only provides further evidence that Dupixent may be contributing to serious cancer risks in certain patients.

Key Warning Signs in Dupixent Users

  • Severe Eczema Patients Be Vigilant: For individuals using Dupixent for severe eczema, the diagnostic challenge is compounded because the drug’s anti-inflammatory action may temporarily mask or alter the appearance of early CTCL symptoms.
  • Be Aware of Warning Signs Early: Warning signs that may differentiate CTCL from typical eczema in Dupixent users include:
    • Failure to respond to treatment: Rashes or lesions that persist, worsen, or spread despite ongoing Dupixent use should raise suspicion of an underlying condition.
    • Progression to plaques and tumors: The development of thicker, raised lesions (plaques) or lumps/nodules (tumors) that can ulcerate is a sign of advancing CTCL not typically seen in standard eczema.
    • Development of systemic symptoms: Advanced CTCL can lead to symptoms not associated with eczema, such as persistently swollen lymph nodes (in the neck, armpits, or groin), unexplained fatigue, or weight loss.
    • Sudden acceleration of symptoms: In some case reports, patients experienced a rapid worsening of skin changes shortly after starting Dupixent, suggesting the drug may accelerate the progression of an undetected lymphoma.
  • Skin Changes and Seeking Immediate Medical Help: If you notice persistent or unusual skin changes while on Dupixent, it is crucial to seek a medical evaluation, including a skin biopsy reviewed by a specialist familiar with cutaneous lymphomas

Current Status of Dupixent and Cancer Lawsuits

  • Individual Lawsuits:Dupixent and cancer lawsuits are in the early stages, with individual lawsuits being filed across the United States.
  • No Class Action or MDL (Yet): There is currently no class action lawsuit or multidistrict litigation (MDL) for Dupixent cases, as the damages are considered too severe and unique to each patient for a single class action. However, consolidation into an MDL is possible as more cases are filed.
  • No Recalls or Settlements: As of November 2025, the FDA has not recalled Dupixent, and no settlements or jury verdicts have been reached.

Who Can Qualify for a Dupixent Cancer Lawsuit?

  • Eligibility: Individuals who used Dupixent and were later diagnosed with cutaneous T-cell lymphoma (CTCL) or related T-cell lymphomas (such as mycosis fungoides or Sézary syndrome) or other severe Dupixent side effects may be eligible to file a personal injury or wrongful death lawsuit.
  • Contact Dupixent Cancer Lawyer Timothy L. Miles: If you or a loved one developed CTCL after using Dupixent, or suffered other severe Dupixent side effects it is recommended to consult with a personal injury attorney promptly, as state laws impose strict deadlines (statutes of limitations) for filing a claim. If you suffered Dupixent and Cancer call Dupixent Cancer Lawyer Timothy L. Miles today for a free case evaluation. (855)-846-6529 or [email protected].

 

Compensation in a Dupixent Cancer Lawsuit

  • Eligible: If you are eligible for a Dupixent Lawsuit, a successful plaintiff is entitled to compensatory damages which would include compensation for things such as:
    • past and future medical expenses;
    • pain and suffering including emotional distress; and
    • lost wages and the reduction in your ability to earn an income.
  • Contact Timothy L. Miles: If your case proceeds to trial it is also possible the court could impose punitive damages, intended to punish the defendant for their actions.  Contact Dupixent Lawyer Timothy L. Miles who can tell you if you are eligible for a Dupixent Cancer Lawsuit and can explain more about the type of damages you are entitled to receive.  (855) 846–6529 or [email protected].

 

If I Was Diagnosed with Dupixent and Cancer, How Do I Get Started?

  • Get a Free Case Evaluation: If you or a loved on developed Dupixent and Cancer after taking Dupixent, the most important thing to do now is get a free case evaluation from a Dupixent Cancer Lawyer to see if you qualify for a Dupixent Cancer Lawsuit. These are not typical cases any lawyer can litigate. Contact Cancer Lawyer Timothy L. Miles who can tell you if you are eligible for a Dupixent Cancer case and can explain more about what will happen next.  (855) 846–6529 or [email protected].
  • Medical Records Review: The earlier your records are reviewed, the stronger the foundation becomes, especially in cases where the biopsy history is limited or where the initial diagnosis was “eczema” that simply never responded the way it should have. A lawyer experienced in drug litigation can help secure the complete medical file, obtain an independent pathology review if necessary, and establish a clear timeline that courts and juries can follow.
  • Time Is of the Essence: If you have a valid case, then it is vital to preserve your rights under the statute of limitations in your state. These deadlines are different in different states, but it normally starts running from the time of diagnosis or from the point when a reasonable person should have realized the connection between the diagnosis and the drug.  Time is of the essence so give Dupixent Cancer Lawyer Timothy L. Miles a call today.

NOTHING red grungy rectangle stamp sign. used in Dupixent and Cancer Risk

 

Contingency Fee Agreements: No Cost to Hire a Lawyer

  • ​​​No Fee:  It does not cost anything to hire a lawyer​ if you are eligible for a Dupixent Cancer Lawsuit. We take all cases on a contingency basis which means we do not get paid unless we win or settle your case.
  • Talk with a Lawyer Free of Charge: A lawyer​ can explain the process of a Dupixent Cancer Lawsuit and answer any questions you may have free of charge. The call is free and so is the fee unless we will or settle your case, so call Dupixent Cancer Lawsuit Timothy L. Miles today to see if you may be entitled to significant compensation.

FREQUENTLY ASKED QUESTIONS ABOUT A DUPIXENT CANCER LAWSUIT

1. How Can a Dupixent Lawyer help me?

When you hire a skilled Lawyer, they will work tirelessly to build a strong case on your behalf. This includes:
  • Thoroughly investigating the details of your case, including your medical history, Dupixent usage, and the onset of your symptoms
  • Gathering and analyzing relevant medical records, scientific studies, and other evidence to support your claims
  • Collaborating with medical experts to provide expert testimony and strengthen your case
  • Negotiating with the pharmaceutical company and their legal team to secure a fair settlement
  • Preparing and filing the necessary legal documents to initiate and progress your lawsuit
  • Representing you in court if litigation becomes necessary
By having a knowledgeable Dupixent Lawyer on your side, you can rest assured that your rights will be protected, and you will have the best possible chance of obtaining the compensation you deserve.

2. What are the potential benefits of a Dupixent Cancer Lawsuit?

If you are eligible for a Lawsuit, you may be entitled to substantial compensation for your medical treatment and for your pain and suffering.

3. How long will the Dupixent Cancer Lawsuit take to resolve?

The duration of lawsuits can vary significantly, depending on the complexity of the case, legal strategies, and whether settlements are reached. It could take several months to years to resolve the lawsuit.

4. What Is Cutaneous T-cell lymphoma?

Cutaneous T-cell lymphoma (CTCL) is a rare, slow-growing cancer of the T-cells (a type of white blood cell) that affects the skin. Symptoms often include itchy, scaly rashes, red patches, plaques, or tumors, and can mimic other skin conditions like eczema, which can delay diagnosis. In some cases, the cancer can spread from the skin to the lymph nodes or other organs. phagitis.
Key characteristics
  • What it is: A type of non-Hodgkin lymphoma that starts in T-cells in the skin.
  • Common symptoms:
    • Itchy, scaly patches or plaques
    • Redness on the skin
    • Thicker, raised lesions or tumors
    • Sometimes, the skin redness can cover a large portion of the body, a condition called erythroderma
    • Progression: CTCL is often slow-growing, but some types can be aggressive and spread to other parts of the body, such as the lymph nodes, blood, or organs like the liver or lungs.
Common types: The two most common types are mycosis fungoides and Sézary syndrome.
  • Diagnosis: Diagnosis can be challenging due to similar-looking symptoms and often involves a skin biopsy, physical exam, blood tests, and imaging.
  • Treatment: Treatments are chosen based on the stage of the cancer and can include creams, light therapy, radiation, or systemic treatments like chemotherapy or other medications.

5. What is cutaneous T-cell lymphoma (CTCL)?

Cutaneous T-cell lymphomas (CTCL) are a wide range and group of extremely rare cancers. Some forms grow slowly and stay in the skin. Less frequently, the cancer can spread from the skin to the blood or a lymph node. Dermatologists often work closely with oncologists (doctors who treat cancer) and other specialists to care for patients who have one of these cancers.

6. How many different types of CTCL are there?

There are several types. The most common types of cutaneous T-cell lymphoma, also known as CTCL cancer or CTCL, are:
  • Mycosis Fungoide (MF) – The most common type, characterized by patches, plaques, and tumors on the skin.
  • Sézary Syndrome (SS) – A more aggressive form of MF that affects the blood as well as the skin.
Other more rare types of CTCL include:
  • Lymphomatoid papulosis – A benign form of CTCL that causes small, itchy bumps on the skin.
  • Granulomatous slack skin – A rare, indolent form of CTCL that causes loose, pendulous folds of skin.
  • Anaplastic large cell lymphoma – An aggressive form of CTCL that can spread to other organs.
  • Extranodal NK/T-cell lymphoma: A rare type of CTCL that affects the skin and lymph nodes.
  • Extranodal NK/T-cell lymphoma, nasal type – A rare, aggressive lymphoma that can affect the skin, among other places.
  • Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) – A rare, slow-growing type that causes nodules deep in the fatty layer of the skin, most often on the legs.
  • Primary cutaneous peripheral T-cell lymphoma (unspecified) – This is a category for rare entities that do not fit into other classifications.

Contact Timothy L. Miles Today About a Dupixent Cancer Lawsuit

If you believe you qualify for a Dupixent Cancer Lawsuit, contact Dupixent Cancer Lawyer Timothy L. Miles today for a free case evaluation to see if you are eligible for a Dupixent Cancer Lawsuit and possible entitled to substantial compensation.  855/846-6529 or via e-mail at [email protected].(24/7/365).

Timothy L. Miles, Esq.
Law Offices of Timothy L. Miles
Tapestry at Brentwood Town Center
300 Centerview Dr. #247
Mailbox #1091
Brentwood,TN 37027
Phone: (855) Tim-MLaw (855-846-6529)
Email: [email protected]
Website: www.classactionlawyertn.com

Logo law office timothy l. miles used in Whistleblower Lawyer in Nashville